| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
Glabrone targets PPAR-γ (Peroxisome Proliferator-Activated Receptor Gamma), functioning as a ligand with significant binding activity. The compound also targets neuraminidase (NA), inhibiting influenza virus release. It modulates key signaling pathways such as NF-κB and PI3K/Akt. As a flavonoid, Glabrone exhibits antioxidant, anti-inflammatory, and anticancer activities through modulation of these pathways. It is a specific UGT1A9 probe substrate.
|
|---|---|
| ln Vitro |
In vitro, Glabrone demonstrates anti-influenza activity by blocking influenza virus release through neuraminidase inhibition. It exhibits significant PPAR-γ ligand-binding activity. The compound shows antioxidant, anti-inflammatory, and anticancer activities. Research suggests it can inhibit proliferation, induce apoptosis, and modulate key signaling pathways such as NF-κB and PI3K/Akt. Glabrone is a specific UGT1A9 probe substrate.
|
| ln Vivo |
In vivo, Glabrone has been studied for its anti-influenza activity. As a PPAR-γ ligand, it may have potential in metabolic and inflammatory disease research. The compound is an isoflavone from licorice with antioxidant, anti-inflammatory, and anticancer activities. Its effects on NF-κB and PI3K/Akt pathways suggest potential for treating inflammatory diseases and cancer. Further in vivo studies are ongoing to fully characterize its therapeutic potential.
|
| Enzyme Assay |
In vitro receptor binding assays for Glabrone involve measuring PPAR-γ ligand-binding activity. PPAR-γ activation is assessed using reporter gene assays or coactivator recruitment assays. Neuraminidase inhibition is assessed by measuring enzymatic activity using fluorogenic substrates. For antioxidant activity, DPPH, ABTS, or other free radical scavenging assays are used. Anti-inflammatory activity is measured by assessing inhibition of pro-inflammatory cytokine production. Anticancer activity is evaluated by assessing inhibition of cancer cell proliferation or induction of apoptosis. Assays are performed in appropriate buffer systems with positive controls.
|
| Cell Assay |
Glabrone cell-based assays are conducted in cancer cell lines, immune cells, and virus-infected cells. Cells are cultured in appropriate media at 37°C with 5% CO2 and treated with Glabrone at varying concentrations. Cell viability is assessed by MTT or CCK-8 assays. Apoptosis is evaluated by Annexin V/PI staining and caspase activity assays. PPAR-γ activation is assessed by measuring target gene expression. NF-κB and PI3K/Akt pathway activation is assessed by Western blot. For antiviral studies, virus-infected cells are treated with the compound and viral replication is measured. Experiments are performed in triplicate with appropriate positive and negative controls.
|
| Animal Protocol |
Glabrone in vivo studies are conducted in animal models of influenza infection, inflammation, and cancer. Animals are treated with Glabrone via oral administration or injection. For antiviral studies, influenza-infected mice are used and viral titers are measured. For anti-inflammatory studies, animal models of inflammation are used. For anti-cancer studies, tumor-bearing mice are used. Dosing regimens are optimized based on pharmacokinetic data. Animals are monitored for clinical signs. Tissues and blood samples are collected for histopathological and biomarker analysis at study endpoints. Studies are conducted in accordance with institutional animal care guidelines.
|
| ADME/Pharmacokinetics |
Glabrone (MW 336.34 g/mol, C20H16O5) is an isoflavone from Glycyrrhiza glabra roots. It is soluble in DMSO at 25 mg/mL (74.33 mM). The compound should be stored at -20°C. Pharmacokinetic parameters such as half-life, bioavailability, and tissue distribution would be determined in species-specific studies. Glabrone is a specific UGT1A9 probe substrate and is used in flavonoid and antiviral research.
|
| Toxicity/Toxicokinetics |
Glabrone is generally well-tolerated in preclinical studies. The compound is a natural isoflavone from licorice with established safety profiles. Its anti-influenza, antioxidant, anti-inflammatory, and anticancer activities have been demonstrated with acceptable safety profiles. No significant adverse effects have been reported in the available literature at research-use concentrations. The compound is intended for research use only. Standard safety precautions should be followed when handling. Comprehensive toxicological evaluation would be required for therapeutic development.
|
| References | |
| Additional Infomation |
Glycyrrhizin is an isoflavone. It has been reported to be found in licorice (Glycyrrhiza uralensis), euphorbia helioscopia, and other organisms with relevant data. See also: Glycyrrhiza glabra (partial).
Glabrone is an isoflavone from Glycyrrhiza glabra roots with anti-influenza activity and significant PPAR-γ ligand-binding activity. It is a specific UGT1A9 probe substrate whose metabolites inhibit influenza virus release by blocking neuraminidase. The compound exhibits antioxidant, anti-inflammatory, and anticancer activities, modulating NF-κB and PI3K/Akt pathways. Its molecular formula is C20H16O5 with a molecular weight of 336.34 g/mol. All applications are limited to non-human research use. |
| Molecular Formula |
C20H16O5
|
|---|---|
| Molecular Weight |
336.3380
|
| Exact Mass |
336.1
|
| CAS # |
60008-02-8
|
| PubChem CID |
5317652
|
| Appearance |
Off-white to light yellow solid powder
|
| Density |
1.368g/cm3
|
| Boiling Point |
554.1ºC at 760 mmHg
|
| Melting Point |
224 - 226 °C
|
| Flash Point |
202.6ºC
|
| Index of Refraction |
1.659
|
| LogP |
4.055
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
25
|
| Complexity |
607
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
COLMVFWKLOZOOP-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C20H16O5/c1-20(2)8-7-14-16(25-20)6-5-12(18(14)22)15-10-24-17-9-11(21)3-4-13(17)19(15)23/h3-10,21-22H,1-2H3
|
| Chemical Name |
7-hydroxy-3-(5-hydroxy-2,2-dimethylchromen-6-yl)chromen-4-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.9732 mL | 14.8659 mL | 29.7318 mL | |
| 5 mM | 0.5946 mL | 2.9732 mL | 5.9464 mL | |
| 10 mM | 0.2973 mL | 1.4866 mL | 2.9732 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
